WASHINGTON – US government scientists are battling calls for one-dose regimens for two Covid-19 vaccines designed to be administered with two injections, saying there is insufficient evidence that a single dose provides long-term protection.
“It is essential that these vaccines are used as authorized by the FDA to prevent Covid-19 and related hospitalizations and deaths,” Peter Marks, director of the center that supervises vaccines at the Food and Drug Administration, told The Wall Street Journal.
The FDA approved a two-dose regimen for vaccines from Moderna Inc at the end of last year..
and a partnership with Pfizer Inc.
and BioNTech SE.
More recently, it approved the use of a single dose regimen for a Johnson & Johnson vaccine.
Some scientists and lawmakers have called for a switch to a single dose regimen for all vaccines, citing preliminary studies showing that one dose can be effective. They say that switching to a dose will allow the United States to accelerate the pace of vaccinations.
In a letter to Acting Secretary of Health and Human Services, Norris Cochran, on March 2, seven medical members of Congress urged the department to “consider issuing a revised emergency use authorization as soon as possible”, which may take the use of a single dose of the Pfizer and Moderna vaccines.
“Last week, the United States passed a worrying milestone of more than 500,000 COVID-19-related deaths,” said the letter, signed by lawmakers including Rep. Andy Harris (R, MD.) And Rep. Gregory F. Murphy, ( R., NC). “These are impressive statistics, and anything we can do to help prevent new tragedies – to further protect the public health and safety of the American people – must be fully employed.”
In interviews, senior scientists from the FDA government and the National Institutes of Health said that such a change is not justified, saying the evidence used to approve the Pfizer and Moderna vaccines was based on two doses.
These scientists said that a dose may offer short-term protection, but long-term protection is a question mark.
“You would be flying blind if you only used one dose,” said a senior scientist and adviser to President Biden. “If you are going to do anything other than follow the studies shown to the FDA, show me that this unique effect is durable.”
Another senior doctor from the U.S. government said that vaccination durability is especially important when more resistant strains of Covid, including those from the UK and South Africa, are appearing in the U.S.
“We think it is better to get people to the highest possible level of immunity,” said the doctor.
The doctor added that the pace of vaccinations is accelerating with Merck’s recent decision to help produce the J&J vaccine.
“We will soon have a good stock of vaccines,” said the doctor.
Representatives from Pfizer and Moderna did not immediately respond to requests for comment on Saturday. Pfizer said earlier that it has no data on the single-dose approach, and Moderna said earlier that it is not studying the subject.
Paul A. Offit of Philadelphia Children’s Hospital, who served on the FDA advisory panel that recommended the use of the Pfizer and Moderna vaccines, said these clinical trials “found a level of neutralizing antibodies [with one dose] this was significantly less than that obtained with two doses ”.
The chairman of the FDA advisory panel, Dr. Arnold Monto, also said that the two-dose regimen is better for the Pfizer and Moderna vaccines. Dr. Monto, a public health doctor at the University of Michigan, emphasized the need for two doses to combat Covid variants.
“We have information about a two-dose strategy,” said Dr. Monto. “We need high levels of antibodies at these doses to deal with the variants.”
Others who hold similar positions in the United States government are prominent infectious physician Anthony Fauci and Andy Slavitt, a senior adviser at the White House to Covid’s response. Slavitt said it would be a mistake for the US government to be persuaded by just one study.
University of Minnesota epidemiologist Michael Osterholm said in testimony on Thursday before the Minnesota legislature that the United States should consider postponing second doses so that more people can get their first injections.
“We could vaccinate more people in our group over the age of 65. I think the data will prove that it is actually a very effective way of doing this. “
Two weeks ago, researchers in Israel reported that a dose of the Pfizer vaccine was 85% effective in preventing symptomatic diseases 15 to 28 days after inoculation.
In the UK, the government has chosen to stretch the supply of vaccines by delaying a second dose by up to 12 weeks in an attempt to reach more people.
British researchers released preliminary data in the past few days saying that either of the two vaccines – from Pfizer and AstraZeneca PLC – reduced the risk of hospitalization among people over 70 by 80%, compared with people of similar ages without vaccination.
AstraZeneca is still conducting a study in the United States of its vaccine, which has not yet obtained authorization from the FDA.
Write to Thomas M. Burton at [email protected]
Copyright © 2020 Dow Jones & Company, Inc. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8